Niagen Bioscience is trading at $2.28, down 9.52%, after its November 4 release showed third-quarter revenue and earnings missed expectations. - Revenue was $27.2 million, down 20% year over year, and the company reported a $0.01-per-share loss. - Adjusted EBITDA was $0.5 million; quarterly operating cash flow was $2.6 million, and cash was $69.5 million. - The release came after regular trading hours. Broader markets rose, while the earnings shortfall provides a company-specific explanation for the decline.